AU2015289874A1 - Crystalline antibody formulations - Google Patents

Crystalline antibody formulations Download PDF

Info

Publication number
AU2015289874A1
AU2015289874A1 AU2015289874A AU2015289874A AU2015289874A1 AU 2015289874 A1 AU2015289874 A1 AU 2015289874A1 AU 2015289874 A AU2015289874 A AU 2015289874A AU 2015289874 A AU2015289874 A AU 2015289874A AU 2015289874 A1 AU2015289874 A1 AU 2015289874A1
Authority
AU
Australia
Prior art keywords
antibody
seq
phosphate
crystals
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015289874A
Other languages
English (en)
Inventor
Nazer Khalaf
Saraswathi MANDAPATI
Reena J. Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2015289874A1 publication Critical patent/AU2015289874A1/en
Priority to AU2021201422A priority Critical patent/AU2021201422A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2015289874A 2014-07-14 2015-07-13 Crystalline antibody formulations Abandoned AU2015289874A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021201422A AU2021201422A1 (en) 2014-07-14 2021-03-04 Crystalline antibody formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462024393P 2014-07-14 2014-07-14
US62/024,393 2014-07-14
PCT/US2015/040217 WO2016010927A1 (en) 2014-07-14 2015-07-13 Crystalline antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021201422A Division AU2021201422A1 (en) 2014-07-14 2021-03-04 Crystalline antibody formulations

Publications (1)

Publication Number Publication Date
AU2015289874A1 true AU2015289874A1 (en) 2017-02-02

Family

ID=53836192

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015289874A Abandoned AU2015289874A1 (en) 2014-07-14 2015-07-13 Crystalline antibody formulations
AU2021201422A Abandoned AU2021201422A1 (en) 2014-07-14 2021-03-04 Crystalline antibody formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021201422A Abandoned AU2021201422A1 (en) 2014-07-14 2021-03-04 Crystalline antibody formulations

Country Status (7)

Country Link
US (2) US20170198059A1 (https=)
EP (1) EP3169710A1 (https=)
JP (3) JP2017525680A (https=)
AU (2) AU2015289874A1 (https=)
CA (1) CA2954767A1 (https=)
MX (1) MX2017000527A (https=)
WO (1) WO2016010927A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11267902B2 (en) * 2014-07-14 2022-03-08 Amgen Inc. Crystalline antibody formulations

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016010924A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
US20170056504A1 (en) * 2015-09-02 2017-03-02 Kenneth I. Kohn Method of extending half-life of crystaline antibodies
EP3596101B1 (en) 2017-03-14 2022-01-05 Amgen Inc. Methods directed to crystalline biomolecules
MA48464A (fr) 2017-04-28 2020-03-04 Amgen Inc Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques
MA48461A (fr) * 2017-04-28 2020-03-04 Amgen Inc Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
JP7213254B2 (ja) * 2017-09-26 2023-01-26 バイオコン バイオロジックス インディア リミテッド ペプチド結晶の分離、洗浄および乾燥のための統合され、自動化された濾過
GB2584687B (en) * 2019-06-11 2023-08-23 Univ Newcastle Crystallisation of chemical molecules

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU698393B2 (en) 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US6020004A (en) 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6432449B1 (en) 1998-05-18 2002-08-13 Amgen Inc. Biodegradable sustained-release alginate gels
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
NZ526720A (en) * 2000-12-28 2007-11-30 Altus Pharmaceuticals Inc Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
US8821086B2 (en) * 2006-12-22 2014-09-02 Tennine Corporation Method and apparatus for controlled-fracture machining
WO2008109871A2 (en) * 2007-03-08 2008-09-12 Irm Llc Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
CN101679527A (zh) * 2007-04-13 2010-03-24 诺瓦提斯公司 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法
US20130072665A1 (en) * 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US9994923B2 (en) * 2008-04-23 2018-06-12 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (PCSK9) variants and uses thereof
KR100985090B1 (ko) * 2008-05-23 2010-10-04 한국과학기술연구원 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
WO2011028938A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2011053783A2 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
PL3395836T3 (pl) * 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140004122A1 (en) * 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
ITPN20110039A1 (it) * 2011-05-24 2012-11-25 Keyline S P A Blocchetto di presa perfezionato per macchina duplicatrice di chiavi
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2849788B1 (en) * 2012-05-17 2018-01-03 Cyon Therapeutics Inc. Proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors for use in treating sepsis and septic shock
EP2861624A1 (en) * 2012-06-15 2015-04-22 F. Hoffmann-La Roche AG Anti-pcsk9 antibodies, formulations, dosing, and methods of use
US20150335615A1 (en) * 2013-01-04 2015-11-26 Toshihisa Kawai Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
WO2014145744A1 (en) * 2013-03-15 2014-09-18 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
JP2016514668A (ja) * 2013-03-15 2016-05-23 アムジエン・インコーポレーテツド プロタンパク質コンベルターゼスブチリシンケクシン９型に結合するヒト抗原結合タンパク質
TW202021614A (zh) * 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
US20150004174A1 (en) * 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
JP6267792B2 (ja) * 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
KR20220048051A (ko) * 2013-10-11 2022-04-19 사노피 바이오테크놀로지 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도
MX2016006226A (es) * 2013-11-12 2016-09-07 Sanofi Biotechnology Regimenes de dosificacion para uso con inhibidores de pcsk9.
US8883157B1 (en) * 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) * 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) * 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
CN106029096A (zh) * 2014-02-14 2016-10-12 瑞泽恩制药公司 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法
EP3107937A4 (en) * 2014-02-21 2017-11-15 MedImmune, LLC Anti-pcsk9~glp-1 fusions and methods for use
WO2015140079A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
AU2015231713B2 (en) * 2014-03-17 2020-11-19 Regeneron Pharmaceuticals, Inc. Methods for reducing cardiovascular risk
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
WO2016010924A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
PL3169353T3 (pl) * 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
EP3197492A1 (en) * 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
WO2017177094A2 (en) * 2016-04-08 2017-10-12 Amgen Inc. Drug delivery device, method of manufacture, and method of use
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
SG10201912565QA (en) * 2016-09-29 2020-02-27 Amgen Inc Low-viscosity antigen binding proteins and methods of making them
EP3522918A1 (en) * 2016-10-06 2019-08-14 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
US20190031774A1 (en) * 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
BR112020007405A2 (pt) * 2017-10-18 2020-12-08 Regenxbio Inc. Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos
JP7332691B2 (ja) * 2018-07-08 2023-08-23 スペシフィカ インコーポレイティド 抗体の開発可能性が最大化された抗体ライブラリー

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11267902B2 (en) * 2014-07-14 2022-03-08 Amgen Inc. Crystalline antibody formulations

Also Published As

Publication number Publication date
AU2021201422A1 (en) 2021-03-25
JP2020172526A (ja) 2020-10-22
EP3169710A1 (en) 2017-05-24
CA2954767A1 (en) 2016-01-21
US20170198059A1 (en) 2017-07-13
US11267902B2 (en) 2022-03-08
US20190127485A1 (en) 2019-05-02
WO2016010927A1 (en) 2016-01-21
JP2017525680A (ja) 2017-09-07
MX2017000527A (es) 2017-08-10
JP2018150337A (ja) 2018-09-27

Similar Documents

Publication Publication Date Title
US11267902B2 (en) Crystalline antibody formulations
US11773184B2 (en) Crystalline antibody formulations
US9920114B2 (en) Antibody formulations
HK1192570A (en) Anti-sclerostin antibody crystals and formulations thereof
HK1192570B (en) Anti-sclerostin antibody crystals and formulations thereof
NZ615624B2 (en) Anti - sclerostin antibody crystals and formulations thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted